1887

Chapter 24 : Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815820/9781555814083_Chap24-1.gif /docserver/preview/fulltext/10.1128/9781555815820/9781555814083_Chap24-2.gif

Abstract:

This chapter reviews both the direct and indirect effects of the introduction of pneumococcal conjugate vaccine into routine use. At this time, available data on vaccine impact are primarily from the United States, reflecting the timing of vaccine introduction. Reports from several sources indicate that the routine use of pneumococcal conjugate vaccine had a profound effect on invasive pneumococcal disease (such as bacteremia, bacteremic pneumonia, and meningitis) in children and that the effect occurred quickly following introduction. The shortages of pneumococcal conjugate vaccine that occurred between 2001 and 2004 meant that many children received an abbreviated two-dose series, received the primary three-dose series without the fourth (booster) dose, or experienced delays in the scheduled administration of doses. Pneumococci are generally transmitted from persons carrying pneumococci in the nasopharynx to others who become carriers; a small percentage of the new carriers will go on to develop disease. The reduction in carriage of vaccine serotypes in children who have received pneumococcal conjugate vaccine means that fewer vaccine serotype pneumococci are circulating among families, in day care centers, and in the community. Conjugate vaccines as currently designed can protect against only a limited number of the 90 pneumococcal serotypes. Data on vaccine impact on carriage and disease following routine introduction have added a wealth of information on top of that learned from clinical trials.

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24

Key Concept Ranking

Pneumococcal Conjugate Vaccine
0.7558872
Acute Otitis Media
0.49528924
Conjugate Vaccines
0.4577041
0.7558872
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Pneumococcal carriage among children <7 years of age in Massachusetts by serotype and quarter Q1 to Q4, 2000 to 2003 ( ). Solid bars, vaccine type; hatched bars, nonvaccine type; open bars, vaccine related, including serotype 19A.

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Coverage with three or more doses of pneumococcal conjugate vaccine among children 19 to 35 months old according to the National Immunization Survey (NIS) and incidence of invasive pneumococcal disease among children <5 years of age by serotype in the CDC’s ABCs areas, 1998 to 2005 (CDC, unpublished data; ).

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Incidence of invasive pneumococcal disease among adults 65 years of age and older by serotype in the CDC’s ABCs areas, 1998 to 2005 (CDC, unpublished data; 13, 47).

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

Change in projected number of episodes of invasive pneumococcal disease in the United States by serotype and age group, 1998/1999 versus 2003. Data are from the CDC’s ABCs ( ).

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815820.ch24
1. Barricarte, A.,, J. Castilla,, A. Gil-Setas,, L. Torroba,, J. A. Navarro-Alonso,, F. Irisarri, and, M. Arriazu. 2007. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin. Infect. Dis. 44:14361441.
2. Barzilay, E. J.,, K. L. O'Brien,, Y. S. Kwok,, R. M. Hoekstra,, E. R. Zell,, R. Reid,, M. Santosham,, C. G. Whitney, and, D. R. Feikin. 2006. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 24:904913.
3. Black, S.,, H. Shinefield,, R. Baxter,, R. Austrian,, L. Bracken,, J. Hansen,, E. Lewis, and, B. Fireman. 2004. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23:485489.
4. Black, S.,, H. Shinefield,, B. Fireman,, E. Lewis,, P. Ray,, J. R. Hansen,, L. Elvin,, K. M. Ensor,, J. Hackell,, G. Siber,, F. Malinoski,, D. Madore,, I. Chang,, R. Kohberger,, W. Watson,, R. Austrian,, K. Edwards, and the Northern California Kaiser Permanente Vaccine Study Center Group. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187195.
5. Black, S. B.,, H. R. Shinefield,, J. Hansen,, L. Elvin,, D. Laufer, and, F. Malinoski. 2001. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20:11051107.
6. Black, S. B.,, H. R. Shinefield,, S. Ling,, J. Hansen,, B. Fireman,, D. Spring,, J. Noyes,, E. Lewis,, P. Ray,, J. Lee, and, J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810815.
7. Block, S. L.,, J. Hedrick,, C. J. Harrison,, R. Tyler,, A. Smith,, R. Findlay, and, E. Keegan. 2004. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis. J. 23:829833.
8. Bluestone, C. D.,, J. S. Stephenson, and, L. M. Martin. 1992. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11:S7S11.
9. Bondy, J.,, S. Berman,, J. Glazner, and, D. Lezotte. 2000. Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric Medicaid cohort. Pediatrics 105:E72.
10. Brueggemann, A. B.,, D. T. Griffiths,, E. Meats,, T. Peto,, D. W. Crook, and, B. G. Spratt. 2003. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis. 187:14241432.
11. Byington, C. L.,, M. H. Samore,, G. J. Stoddard,, S. Barlow,, J. Daly,, K. Korgenski,, S. Firth,, D. Glover,, J. Jensen,, E. O. Mason,, C. K. Shutt, and, A. T. Pavia. 2005. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin. Infect. Dis. 41:2129.
12. Casey, J. R., and, M. E. Pichichero. 2004. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr. Infect. Dis. J. 23:824828.
13. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998–2003. Morb. Mortal. Wkly. Rep. 54:893897.
14. Centers for Disease Control and Prevention. 2006, Posting date. Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19–35 of age by state and local area US, National Immunization Survey, Q1/2006–Q4/2006. http://www.cdc.gov/vaccines/stats-surv/nis/tables/06/tab02_antigen_iapxls
15. Centers for Disease Control and Prevention. 2001. Notice to readers: decreased availability of pneumococcal conjugate vaccine. Morb. Mortal. Wkly. Rep. 50:783784.
16. Centers for Disease Control and Prevention. 2004. Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. Morb. Mortal. Wkly. Rep. 53:177178.
17. Centers for Disease Control and Prevention. 2000. Prevention of pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly. Rep. 49(RR-9):135.
18. Cutts, F.,, S. Zaman,, G. Enwere,, S. Jaffar,, O. Levine,, J. Okoko,, C. Oluwalana,, A. Vaughan,, S. Obaro,, A. Leach,, K. McAdam,, E. Biney,, M. Saaka,, U. Onwuchekwa,, F. Yallop,, N. Pierce,, B. Greenwood, and, R. Adegbola. 2005. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365:11391146.
19. Dagan, R.,, N. Givon-Lavi,, O. Zamir,, M. Sikuler-Cohen,, L. Guy,, J. Janco,, P. Yagupsky, and, D. Fraser. 2002. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185:927936.
20. Dworkin, M. S.,, J. W. Ward,, D. L. Hanson,, J. L. Jones,, J. E. Kaplan, and Adult and Adolescent Spectrum of HIV Disease Project. 2001. Pneumococcal disease among HIV-infected persons: incidence, risk factors, and impact of vaccination. Clin. Infect. Dis. 32:794800.
21. Eskola, J.,, T. Kilpi,, A. Palmu,, J. Jokinen,, J. Haapakoski,, E. Herva,, A. Takala,, H. Kayhty,, P. Karma,, R. Kohberger,, G. Siber,, P. H. Makela, and the Finnish Otitis Media Study Group. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403409.
22. Flannery, B.,, S. Schrag,, N. M. Bennett,, R. Lynfield,, L. H. Harrison,, A. Reingold,, P. R. Cieslak,, J. Hadler,, M. M. Farley,, R. R. Facklam,, E. R. Zell, and, C. G. Whitney. 2004. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 291:21972203.
23. Flannery, B. L.,, R. T. Heffernan,, L. H. Harrison,, S. M. Ray,, A. L. Reingold,, J. Hadler,, W. Schaffner,, R. Lynfield,, A. R. Thomas,, J. Li,, M. Campsmith,, C. G. Whitney, and, A. Schuchat. 2006. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann. Intern. Med. 144:19.
24. Ghaffar, F.,, T. Barton,, J. Lozano,, L. S. Muniz,, P. Hicks,, V. Gan,, N. Ahmad, and, G. H. J. McCracken. 2004. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis. 39:930938.
25. Grijalva, C. G.,, J. P. Nuorti,, P. G. Arbogast,, S. W. Martin,, K. M. Edwards, and, M. R. Griffin. 2007. Decline in pneumonia hospitalizations following routine childhood immunization with pneumococcal conjugate vaccine in the United States. Lancet 369:11791186.
26. Haddy, R. I.,, K. Perry,, C. E. Chacko,, W. B. Helton,, M. G. Bowling,, S. W. Looney, and, G. E. Buck. 2005. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr. Infect. Dis. J. 24:320323.
27. Hammitt, L. L.,, D. L. Bruden,, J. C. Butler,, H. C. Baggett,, D. A. Hurlburt,, A. Reasonover, and, T. W. Hennessy. 2006. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193:14871494.
28. Hansen, J.,, S. Black,, H. Shinefield,, T. Cherian,, J. Benson,, B. Fireman, et al. 2006. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr. Infect. Dis. J. 25:779781.
29. Hennessy, T. W.,, R. J. Singleton,, L. R. Bulkow,, D. L. Bruden,, D. A. Hurlburt,, D. Parks,, M. Moore,, A. J. Parkinson,, A. Schuchat, and, J. C. Butler. 2005. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaskan Natives: progress towards elimination of a health disparity. Vaccine 23:54645473.
30. Hicks, L. A.,, L. H. Harrison,, B. Flannery,, J. L. Hadler,, W. Schaffner,, A. S. Craig,, D. Jackson,, A. Thomas,, B. Beall,, R. Lynfield,, A. Reingold,, M. M. Farley,, C. G. Whitney, and the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. 2007. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis. 196:13461354.
31. Hsu, K.,, S. Pelton,, S. Karumuri,, D. Heisey-Grove,, J. Klein, and Massachusetts Department of Public Health Epidemiologists. 2005. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr. Infect. Dis. J. 24:1723.
32. Huang, S. S.,, R. Platt,, S. L. Rifas-Shiman,, S. I. Pelton,, D. Goldmann, and, J. A. Finkelstein. 2005. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116:e408e413.
33. Jones, V. F.,, C. Harrison,, G. G. Stout, and, J. Hopkins. 2005. Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr. Infect. Dis. J. 24:969973.
34. Kaplan, S. L.,, E. O. J. Mason,, E. R. Wald,, G. E. Schutze,, J. S. Bradley,, T. Q. Tan,, J. A. Hoffman,, L. B. Givner,, R. Yogev, and, W. J. Barson. 2004. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113:443449.
35. Kellner, J. D.,, D. L. Church,, J. MacDonald,, G. J. Tyrrell, and, D. Scheifele. 2005. Progress in the prevention of pneumococcal infection. Can. Med. Assoc. J. 173:11491151.
36. Kilpi, T.,, E. Herva,, T. Kaijalainen,, R. Syrjanen, and, A. K. Takala. 2001. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr. Infect. Dis. J. 20:654662.
37. Kim, N.-H.,, S.-H. Kim,, J.-A. Lee,, E.-H. Choi, and, H.-J. Lee. 2006. Changes of serotype distribution of Streptococcus pneumoniae isolate from children in Korea over a 15-year period, 1994–2005, abstr. 645. Final Program Abstr. 44th Annu. Meet. Infect. Dis. Soc. Am., Toronto, Canada.
38. Klugman, K. P.,, S. A. Madhi,, R. E. Huebner,, R. Kohberger,, N. Mbelle,, N. Pierce, and Vaccine Trialists Group. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:13411348.
39. Levine, O. S.,, K. L. O'Brien,, M. Knoll,, R. A. Adegbola,, S. Black,, T. Cherian,, R. Dagan,, D. Goldblatt,, A. Grange,, B. Greenwood,, T. Hennessy,, K. P. Klugman,, S. A. Madhi,, K. Mulholland,, H. Nohynek,, M. Santosham,, S. K. Saha,, J. A. Scott,, S. Sow,, C. G. Whitney, and, F. Cutts. 2006. Pneumococcal vaccination in developing countries. Lancet 367:18801882.
40. Lexau, C. A.,, R. Lynfield,, R. Danila,, T. Pilishvili,, R. Facklam,, M. M. Farley,, L. H. Harrison,, W. Schaffner,, A. Reingold,, N. M. Bennett,, J. Hadler,, P. R. Cieslak,, C. G. Whitney, and the Active Bacterial Core Surveillance Team. 2005. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:20432051.
41. Lopalco, P. L., and Editorial Team. 2006. Use of 7-valent pneumococcal conjugate vaccine in EU. Euro. Surveill. 11:E061207.3.
42. Mahon, B. E.,, K. Hsu,, S. Karumuri,, S. L. Kaplan,, E. O. Mason, Jr.,, S. I. Pelton, U. S. Pediatric Multicenter pneumococcal Surveillance Group, and Massachusetts Department of Public Health Epidemiologists. 2006. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 24:25142520.
43. Mbelle, N.,, R. E. Huebner,, A. D. Wasas,, A. Kimura,, I. Chang, and, K. P. Klugman. 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:11711176.
44. McBean, A. M.,, Y.-T. Park,, D. Caldwell, and, X. Yu. 2005. Declining invasive pneumococcal disease in the U.S. elderly. Vaccine 23:56415645.
45. McEllistrem, M. C.,, J. Adams,, E. O. Mason, and, E. R. Wald. 2003. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J. Infect. Dis. 188:16791684.
46. Moore, M. R.,, T. B. Hyde,, T. W. Hennessy,, D. J. Parks,, A. L. Reasonover,, M. Harker-Jones,, J. Gove,, D. L. Bruden,, K. Rudolph,, A. Parkinson,, J. C. Butler, and, A. Schuchat. 2004. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J. Infect. Dis. 190:20312038.
47. Moore, M. R.,, T. Pilishvili,, A. Thomas, et al. 2006. Geographic trends in invasive pneumococcal disease caused by nonvaccine serotypes, abstr. 636. Final Program Abstr. 44th Annu. Meet. Infect. Dis. Soc. Am., Toronto, Canada.
48. Mufson, M. A., and, R. J. Stanek. 2004. Epidemiology of invasive Streptococcus pneumoniae infections and vaccine implications among children in a West Virginia community, 1978–2003. Pediatr. Infect. Dis. J. 23:779781.
49. Mulholland, K. 1999. Strategies for the control of pneumococcal diseases. Vaccine 17:S79S84.
50. National Advisory Committee on Immunization. 2002. Statement on recommended use of pneumococcal conjugate vaccine. Can. Commun. Dis. Rep. 28:132.
51. National Health Service Immunisation Information. 8 February 2006, Posting date. Pneumococcal vaccine added to the childhood immunisation programme; more protection against meningitis and septicaemia. National Health Service, London, United Kingdom. http://www.immunisation.nhs.uk/newsitem.php?id-56.
52. Nelson, J. C.,, C. G. Whitney,, O. Yu,, M. L. Jackson,, T. Scott,, L. Bounds,, A. Zavitkovsky, and, L. A. Jackson. 2006. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia, abstr. SY 4.05, p. 72. Fifth Int. Symp. Pneumococci Pneumococcal Dis., Alice Springs, Australia.
53. Nuorti, J. P.,, J. C. Butler,, L. Gelling,, J. L. Kool,, A. L. Reingold, and, D. J. Vugia. 2000. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann. Intern. Med. 132:182190.
54. O'Brien, K. L., and, R. Dagan. 2003. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21:18151825.
55. O'Brien, K. L.,, L. H. Moulton,, R. Reid,, R. Weatherholtz,, J. Oski,, L. Brown,, G. Kumar,, A. Parkinson,, D. Hu,, J. Hackell,, I. Chang,, R. Kohberger,, G. Siber, and, M. Santosham. 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362:355361.
56. Pai, R.,, M. R. Moore,, T. Pilishvili,, R. E. Gertz,, C. G. Whitney,, B. Beall, and Active Bacterial Core Surveillance Team. 2005. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192:19881995.
57. Pelton, S. I.,, A. M. Loughlin, and, C. D. Marchant. 2004. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr. Infect. Dis. J. 23:10151022.
58. Poehling, K. A.,, B. J. Lafleur,, P. G. Szilagyi,, K. M. Edwards,, E. Mitchel,, R. Barth,, B. Schwartz, and, M. R. Griffin. 2004. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 114:755761.
59. Poehling, K. A.,, P. G. Szilagyi,, C. G. Grijalva,, S. W. Martin,, B. LaFleur,, E. Mitchel,, R. D. Barth,, J. P. Nuorti, and, M. R. Griffin. 2007. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119:707715.
60. Poehling, K. A.,, T. R. Talbot,, M. R. Griffin,, A. S. Craig,, C. G. Whitney,, E. Zell,, C. A. Lexau,, A. R. Thomas,, L. H. Harrison,, A. L. Reingold,, J. L. Hadler,, M. M. Farley,, B. J. Anderson, and, W. Schaffner. 2006. Invasive pneumococcal disease among young infants before and after pneumococcal conjugate vaccine introduction. JAMA 295:16681674.
61. Ray, G. T.,, C. G. Whitney,, B. A. Fireman,, V. Ciuryla, and, S. B. Black. 2006. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first five years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25:494501.
62. Revai, K.,, D. P. McCormick,, J. Patel,, J. J. Grady,, K. Saeed, and, T. Chonmaitree. 2006. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117:18231829.
63. Robinson, K. A.,, W. Baughman,, G. Rothrock,, N. L. Barrett,, M. Pass,, C. Lexau,, B. Damaske,, K. Stefonek,, B. Barnes,, J. Patterson,, E. R. Zell,, A. Schuchat,, C. G. Whitney, and Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. 2001. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA 285:17291735.
64. Roche, P. W.,, V. L. Krause,, M. Bartlett,, D. Coleman,, H. Cook,, C. Davis, et al. 2006. Invasive pneumococcal disease in Australia, 2004. Commun. Dis. Intell. 30:8092.
65. Sante et Services Sociaux Quebec. November 2004, Posting date. Vaccination provides good protection. Sante et Services Sociaux Quebec, Quebec, Canada. http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/feuillets_ang/f1.pdf
66. Schappert, S. M., and, C. W. Burt. 2006. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat. 13:166.
67. Shafinoori, S.,, C. C. Ginocchio,, A. J. Greenberg,, E. Yeoman,, M. Cheddie, and, L. G. Rubin. 2005. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr. Infect. Dis. J. 24:1016.
68. Singleton, R. J.,, T. W. Hennessy,, L. R. Bulkow,, L. L. Hammitt,, T. Zulz,, D. A. Hurlburt,, J. C. Butler,, K. Rudolph, and, A. Parkinson. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:17841792.
69. Whitney, C. G.,, M. M. Farley,, J. Hadler,, K. H. Harrison,, N. M. Bennett,, R. Lynfield,, A. Reingold,, P. R. Cieslak,, T. Pilsihvili,, D. Jackson,, R. R. Facklam,, J. Jorgensen, and, A. Schuchat. 2003. Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:17371746.
70. Whitney, C. G.,, T. Pilishvili,, M. M. Farley,, W. Schaffner,, A. S. Craig,, R. Lynfield,, A. C. Nyquist,, K. A. Gershman,, M. Vazquez,, N. M. Bennett,, A. Reingold,, A. Thomas,, M. P. Glode,, E. R. Zell,, J. H. Jorgensen,, B. Beall, and, A. Schuchat. 2006. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:14951502.
71. Wise, R. P.,, J. Iskander,, R. D. Pratt,, S. Campbell,, R. Ball,, R. P. Pless, and, M. M. Braun. 2004. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 292:17021710.
72. Zhou, W.,, V. Pool,, J. K. Iskander,, R. English-Bullard,, R. Ball,, R. P. Wise,, P. Haber,, R. P. Pless,, G. Mootrey,, S. S. Ellenberg,, M. M. Braun, and, R. T. Chen. 2003. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS), United States, 1991–2001. Morb. Mortal. Wkly. Rep. Surveill. Summ. 52:124.

Tables

Generic image for table
Table 1

Introduction of seven-valent pneumococcal conjugate vaccine into national immunization programs, as of January 2007

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24
Generic image for table
Table 2

Impact of routine pneumococcal conjugate vaccine use on incidence of invasive disease in children, by age group and serotype

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24
Generic image for table
Table 3

Observational (retrospective) studies evaluating effectiveness of pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes in young children

Citation: Whitney C, Moore M. 2008. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice, p 353-368. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch24

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error